Astrazeneca's (AZN) Imfinzi in combination with chemotherapy has been approved in the European Union for the treatment of adults with operable non-small cell lung cancer.
The specific indication for the treatment of patients at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, the company said Friday.
Under the treatment plan, patients are treated with the drug, also known as durvalumab, in combination with neoadjuvant chemotherapy before surgery and as an adjuvant monotherapy after surgery, the company said.
The European Commission approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use as well as results from a clinical trial in which the drug resulted in a 32% reduction in recurrence, progression, or death vs patients treated with chemotherapy alone, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。